Investigating Fabry disease - some lessons learned

Abstract

Despite recent advances, there is still much to be learned about the pathogenesis of Fabry disease. The categorization of GLA gene missense mutations has been complicated by the fact that some missense variants may fall into more than one category. For instance, the A143T variant may cause late-onset Fabry disease in some subjects and not result in Fabry disease in others (pseudo-deficient). Efforts to mitigate the pathobiology of α-galactosidase A deficiency should differentiate between damaging (maladaptive) consequences and compensatory (adaptive) changes. Current therapy leaves a significant unmet need, especially concerning cardiovascular complications and cardiological clinical outcomes. Non-Fabry-specific therapy is necessary and quite beneficial and must be utilized. Its contribution should be considered when trying to assess the net effect of Fabry-specific therapy. Enzyme replacement therapy (ERT) can be administered to patients independently of their GLA genotype, as it slows the decline of kidney function in most patients if initiated sufficiently early in the disease course. Migalastat has better tissue penetration than ERT, but its usefulness is restricted to patients with amenable missense GLA variants. However, it is important to realize that in a substantial proportion of common amenable mutations, migalastat increases α-galactosidase A activity level beyond the disease threshold and thus eliminates the metabolic disturbance that is at the center of Fabry disease. Substrate reduction therapy and gene therapy approaches are being developed, but these therapeutic modalities have their own limitations and difficulties.

Keywords

Pathogenesis / lysosomal disease / ERT / pharmacological chaperone / gene therapy / GLA variant

References

[1] Arends M,Hughes D.Characterization of classical and nonclassical fabry disease: a multicenter study.J Am Soc Nephrol2017;28:1631-41 PMCID:PMC5407735

[2] Desnick RJ,Eng CM.α-galactosidase a deficiency: fabry disease. In: The online metabolic and molecular bases of inherited disease. New York: McGraw-Hill Education; 2019. Available from: https://www.donornetworkwest.org/wp-content/uploads/uaga_final_aug09.pdf [Last accessed on 31 Jan 2023]

[3] Schiffmann R,Clarke LA.Is it fabry disease?.Genet Med2016;18:1181-5

[4] Benjamin ER,Wu X.The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.Genet Med2017;19:430-8 PMCID:PMC5392595

[5] Schiffmann R.Fabry disease.Pharmacol Ther2009;122:65-77

[6] Lenders M,Kurschat C.Alpha-galactosidase A p.A143T, a non-fabry disease-causing variant.Orphanet J Rare Dis2016;11:54 PMCID:PMC4855861

[7] Valtola K,Hedman M.Cardiomyopathy associated with the Ala143Thr variant of the α-galactosidase A gene.Heart2020;106:609-15. PMCID:PMC7146944

[8] Terryn W,Hemelsoet D.Questioning the pathogenic role of the GLA p.Ala143Thr “mutation” in fabry disease: implications for screening studies and ERT.JIMD Rep2013;8:101-8 PMCID:PMC3565658

[9] Warnock DG.7th Update on fabry disease: biomarkers, progression and treatment opportunities in 2022.Nephron2022;146 Suppl 1:1-51

[10] Valtola K,Kantola I.Late-onset and classic phenotypes of fabry disease in males with the GLA-Thr410Ala mutation.Open Heart2023;10:e002251. PMCID:PMC10030781

[11] Santostefano M,Gibertoni D.Fabry disease nephropathy: histological changes with nonclassical mutations and genetic variants of unknown significance.Am J Kidney Dis2023;82:581-596.e0

[12] Johnson B,Mascher D.Analysis of lyso-globotriaosylsphingosine in dried blood spots.Ann Lab Med2013;33:274-8 PMCID:PMC3698306

[13] Viall S,Yang A.Newborn screening for fabry disease in oregon: approaching the iceberg of a143t and variants of uncertain significance.Am J Med Genet C Semin Med Genet2022;190:206-14

[14] Burton BK,Hoganson GE.Newborn screening for lysosomal storage disorders in illinois: the initial 15-month experience.J Pediatr2017;190:130-5.

[15] Macklin S,Lisi E,Smith E.The psychosocial impact of carrying a debated variant in the GLA gene.J Genet Couns2018;27:217-24.

[16] Sudhan M,Patil R,Hasan Mufti A.Asn215Ser, Ala143Thr, and Arg112Cys variants in α-galactosidase A protein confer stability loss in Fabry's disease.J Biomol Struct Dyn2023;41:9840-9

[17] Braun F,Sellung D.Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.J Clin Invest2023;133:e157782

[18] Shen JS,Moore DF.Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.Mol Genet Metab2008;95:163-8 PMCID:PMC2593623

[19] Delaleu N,Strauss P.Systems analyses of the fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing.Kidney Int2023;104:803-19

[20] Ryter SW,Smith A.Autophagy in vascular disease.Proc Am Thorac Soc2010;7:40-7 PMCID:PMC3137148

[21] Showalter MR,Nagourney A,Carraway KL 3rd.The emerging and diverse roles of bis(monoacylglycero) phosphate lipids in cellular physiology and disease.Int J Mol Sci2020;21:8067 PMCID:PMC7663174

[22] Hein LK,Fuller M.Selective reduction of bis(monoacylglycero)phosphate ameliorates the storage burden in a THP-1 macrophage model of Gaucher disease.J Lipid Res2013;54:1691-7 PMCID:PMC3646469

[23] Medoh UN,Chen JY.The Batten disease gene product CLN5 is the lysosomal bis(monoacylglycero)phosphate synthase.Science2023;381:1182-9.

[24] Ilnytska O,Gorshkov K.Enrichment of NPC1-deficient cells with the lipid LBPA stimulates autophagy, improves lysosomal function, and reduces cholesterol storage.J Biol Chem2021;297:100813 PMCID:PMC8294588

[25] Chen JYS,Lim CO,Tan NS.Lessons on drug development: a literature review of challenges faced in nonalcoholic fatty liver disease (NAFLD) clinical Trials.Int J Mol Sci2022;24:158 PMCID:PMC9820446

[26] Forrester SJ,Hernandes MS,Griendling KK.Reactive oxygen species in metabolic and inflammatory signaling.Circ Res2018;122:877-902. PMCID:PMC5926825

[27] Bassoy EY,Martinvalet D.Reactive oxygen species: do they play a role in adaptive immunity?.Front Immunol2021;12:755856 PMCID:PMC8653250

[28] Bozic M,Rodrigues-Diez RR.Protective role of renal proximal tubular alpha-synuclein in the pathogenesis of kidney fibrosis.Nat Commun2020;11:1943. PMCID:PMC7181766

[29] Oliveira LM,Botelho MG.Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells.Cell Death Dis2015;6:e1994. PMCID:PMC4670926

[30] Book A,Candido T.SNCA Multiplication investigators of the GEoPD consortiumA meta-analysis of α-synuclein multiplication in familial parkinsonism.Front Neurol2018;9:1021 PMCID:PMC6297377

[31] Nelson MP,O'Quinn DB.Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice.Acta Neuropathol Commun2014;2:20 PMCID:PMC3933238

[32] Bangari DS,Desnick RJ.α-galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of fabry disease.Am J Pathol2015;185:651-65

[33] Noben-Trauth K,Brady RO.Normal hearing in alpha-galactosidase A-deficient mice, the mouse model for fabry disease.Hear Res2007;234:10-4.

[34] Schiffmann R,Linthorst GE.Conference ParticipantsScreening, diagnosis, and management of patients with fabry disease: conclusions from a "kidney disease: improving global outcomes" (KDIGO) controversies conference.Kidney Int2017;91:284-93

[35] Schiffmann R.Enzyme replacement in fabry disease: the essence is in the kidney.Ann Intern Med2007;146:142-4

[36] Suarez MLG,Hansrivijit P.Outcomes of kidney transplantation in fabry disease: a meta-analysis.Diseases2020;9:2 PMCID:PMC7838795

[37] Pieroni M,Arbustini E.Cardiac involvement in fabry disease: JACC review topic of the week.J Am Coll Cardiol2021;77:922-36.

[38] Moore DF,Askari H.The cerebral vasculopathy of fabry disease.J Neurol Sci2007;257:258-63

[39] Burand AJ Jr.Fabry disease pain: patient and preclinical parallels.Pain2021;162:1305-21 PMCID:PMC8054551

[40] Orsborne C,Naish JH.Disease-specific therapy for the treatment of the cardiovascular manifestations of fabry disease: a systematic review.Heart2024;110:19-26

[41] Germain DP,Falissard B.The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts.Mol Genet Metab Rep2019;19:100454 PMCID:PMC6365982

[42] Ramaswami U,Hughes D.FOS Study GroupCardio- renal outcomes with long- term agalsidase alfa enzyme replacement therapy: a 10- year fabry outcome survey (FOS) analysis.Drug Des Devel Ther2019;13:3705-15 PMCID:PMC6819672

[43] Nordin S,Vijapurapu R.Myocardial storage, inflammation, and cardiac phenotype in fabry disease after one year of enzyme replacement therapy.Circ Cardiovasc Imaging2019;12:e009430 PMCID:PMC6924943

[44] Shen JS,Day TS.Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in fabry mice.J Inherit Metab Dis2016;39:293-303 PMCID:PMC4754329

[45] Lenders M.Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in fabry disease.Drugs2021;81:1969-81 PMCID:PMC8602155

[46] Nowak A,Monzambani V,Barbey F.Agalsidase-β should be proposed as first line therapy in classic male fabry patients with undetectable α-galactosidase A activity.Mol Genet Metab2022;137:173-8

[47] Schiffmann R,Wang X,Ries M.A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced fabry disease.J Inherit Metab Dis2015;38:1129-36

[48] Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease. Available from: https://www.prnewswire.com/news-releases/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-fda-approval-of-elfabrio-pegunigalsidase-alfa-iwxj-for-the-treatment-of-fabry-disease-301820680.html [Last accessed on 18 Jan 2024]

[49] European Medicines Agency. Homepage. Available from: https://www.ema.europa.eu/en/homepage [Last accessed on 18 Jan 2024]

[50] Schiffmann R,Holida M.Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1/2 clinical trial.J Inherit Metab Dis2019;42:534-44

[51] Wallace E,Holida B.First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study.Mol Genet Metab2023;138:107351.

[52] Baba M,Horio M.Longitudinal study of the decline in renal function in healthy subjects.PLoS One2015;10:e0129036 PMCID:PMC4464887

[53] McCambridge J,Elbourne DR.Systematic review of the hawthorne effect: new concepts are needed to study research participation effects.J Clin Epidemiol2014;67:267-77 PMCID:PMC3969247

[54] Bernat J,Longo N.Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study.Mol Genet Metab2023;138:107027.

[55] Wu YS,Schmith V.Migalastat tissue distribution: extrapolation from mice to humans using pharmacokinetic modeling and comparison with agalsidase beta tissue distribution in mice.Clin Pharmacol Drug Dev2021;10:1075-88. PMCID:PMC8453552

[56] Johnson FK,Castelli J.Comparison of integrated white blood cell alpha-galactosidase a activity exposure between every-other-day orally administered migalastat and biweekly infusions of agalsidase beta or agalsidase alfa.Mol Genet Metab2016;117:S63

[57] Müntze J,Maniuc O.Oral Chaperone therapy migalastat for treating fabry disease: enzymatic response and serum biomarker changes after 1 year.Clin Pharmacol Ther2019;105:1224-33 PMCID:PMC6590383

[58] Germain DP,Nicholls K.Treatment of fabry's disease with the pharmacologic chaperone migalastat.N Engl J Med2016;375:545-55

[59] Gilchrist M,Tyrrell JS.Prevalence of fabry disease-causing variants in the UK Biobank.J Med Genet2023;60:391-6 PMCID:PMC10086508

[60] Lavalle L,Beaton B.Phenotype and biochemical heterogeneity in late onset fabry disease defined by N215S mutation.PLoS One2018;13:e0193550. PMCID:PMC5886405

[61] Lenders M,Brand E.In vitro and in vivo amenability to migalastat in fabry disease.Mol Ther Methods Clin Dev2020;19:24-34 PMCID:PMC7490640

[62] Modrego A,Godino A,Barra JL.Human α-galactosidase a mutants: priceless tools to develop novel therapies for fabry disease.Int J Mol Sci2021;22:6518 PMCID:PMC8234732

[63] Bichet DG,Auray-Blais C.Assessment of plasma lyso-Gb₃ for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.Genet Med2021;23:192-201 PMCID:PMC7790748

[64] Deegan PB,Geberhiwot T.Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.Mol Genet Metab2023;138:106963 PMCID:PMC9918698

[65] Guérard N,Nordbeck P.Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with fabry disease on enzyme replacement.Clin Pharmacol Ther2018;103:703-11.

[66] Weiss AC. Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease. Available from: https://ml-eu.globenewswire.com/Resource/Download/ba4842fd-18bd-4873-97d2-cd73bc3a7371 [Last accessed on 18 Jan 2024]

[67] Shemesh E,Bembi B.Enzyme replacement and substrate reduction therapy for Gaucher disease.Cochrane Database Syst Rev2015;2015:CD010324.

[68] Jabbarzadeh-Tabrizi S,Day TS.Assessing the role of glycosphingolipids in the phenotype severity of fabry disease mouse model.J Lipid Res2020;61:1410-23 PMCID:PMC7604726

[69] Lakomá J,Ferrer Montiel A,Liguori R.Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.Mol Pain2016;12:174480691666372 PMCID:PMC5009828

[70] Burlina AP,Politei JM.Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.BMC Neurol2011;11:61

[71] Kuzmin DA,Johnston NR.The clinical landscape for AAV gene therapies.Nat Rev Drug Discov2021;20:173-4

[72] Rodríguez-Márquez E,Büning H.Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.Expert Opin Biol Ther2021;21:749-66.

[73] Yasuda M,Pagant S.AAV2/6 gene therapy in a murine model of fabry disease results in supraphysiological enzyme activity and effective substrate reduction.Mol Ther Methods Clin Dev2020;18:607-19 PMCID:PMC7396970

[74] Sharma A,Hansen ET,Mohan RR.Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts.Brain Res Bull2010;81:273-8 PMCID:PMC2814910

[75] Hopkin RJ,Deegan P.STAAR, a phase I/II study of isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: Dose escalation phase results.Mol Genet Metab2023;138:107152

[76] Romano R,Pios A,Selby MJ.Development of a B cell protein factory to produce sustained therapeutic levels of alpha-galactosidase A for the treatment of Fabry disease.Mol Genet Metab2023;138:107298.

[77] Schiffmann R,Vockley G. Cardiac effects of 4D-310 in adults with fabry disease in a phase 1/2 clinical trial: functional, quality of life, and imaging endpoints in patients with 12 months of follow up. Available from: https://www.cgtlive.com/view/fabry-disease-gene-therapy-demonstrates-clinically-meaningful-improvements [Last accessed on 18 Jan 2024]

[78] Khan A,Huang J.Lentivirus-mediated gene therapy for fabry disease.Nat Commun2021;12:1178 PMCID:PMC7907075

[79] Mechtler TP,Metz TF.Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.Lancet2012;379:335-41.